Editor's Note: At a recent major oncology conference, Professor Johann de Bono from the Royal Marsden Hospital presented Abstract 17, detailing the preliminary results of a first-in-human Phase 1 dose-escalation trial. The study evaluated VAR5500, a dual-masked pro-X10 T-cell engager targeting PSMA and CD3, in patients with metastatic castration-resistant prostate cancer (mCRPC). This study provides critical proof-of-concept data for the next generation of precision immunotherapy in solid tumors.01 Mechanism of Action: The “Dual-Masking” Strategy for Precision Targeting
- Clinical Context & Challenges: While T-cell engagers have revolutionized hematologic oncology, their application in solid tumors like prostate cancer has been severely hindered by systemic toxicity, particularly Cytokine Release Syndrome (CRS).
- Latest Research Progress: VAR5500 is a bispecific T-cell engager designed with a “dual-masked” protein cover around its antigen-binding sites. This mask prevents the systemic activation of T-cells. The therapeutic remains inactive until it reaches the tumor microenvironment, where proteolytic cleavage by tumor-secreted enzymes unmasks the antibody, allowing it to bind strictly to PSMA on tumor cells and CD3 on T-cells.
- Expert Insight: Prof. de Bono emphasized that this design ensures the active therapeutic is delivered primarily to the tumor site, effectively “decoupling” anti-tumor activity from systemic immune-related toxicity.
02 Safety Profile: Abrogating CRS Without Mandatory Prophylaxis
- Clinical Context & Challenges: Traditional T-cell engagers often require mandatory prophylaxis with corticosteroids or anti-IL-6 therapies (e.g., tocilizumab) to manage CRS, which can complicate treatment and potentially dampen the anti-tumor immune response.
- Latest Research Data: The trial explored ascending doses up to 4000 µg/kg. While reversible blurred vision was noted in two subjects at the highest dose level, the drug was otherwise well-tolerated. Notably, patients were not given steroid or anti-IL-6 prophylaxis (except for a small cohort of three patients at the 4000 µg/kg level). CRS Incidence: Minimal CRS was observed overall, consisting primarily of Grade 1 pyrexia (fever). Severity: No Grade 3 or higher CRS events were reported. Tumor Pain: Immediate tumor-site pain was observed post-infusion in several subjects, serving as a clinical indicator of localized, targeted T-cell activation.
03 Clinical Efficacy: Deep and Durable PSA Responses in Heavily Pre-Treated Populations
- Clinical Context & Challenges: The study enrolled a late-line population that had progressed on most available standard-of-care treatments, including taxanes, androgen receptor pathway inhibitors (ARPIs), and even prior radioligand therapies.
- Latest Research Data: The patient cohort was heavily pre-treated, with 45% having visceral metastases (including ~20% with liver metastases) and nearly all having bone metastases. Efficacy was dose-dependent, with significant biochemical responses observed at doses ≥3000 µg/kg: PSA50 Response: 82% of patients achieved a ≥50% reduction in PSA. PSA90 Response: 53% of patients achieved a ≥90% reduction in PSA. PSA99 Response: 29% of patients in this late-stage population achieved a near-complete PSA response (≥99%).
04 Radiographic Evidence and Case Studies: Sustained Disease Regression
- Latest Research Data: Beyond PSA metrics, VAR5500 demonstrated impressive radiographic activity. In the 11 evaluable subjects, the RECIST objective response rate was 45% (5/11). Significant case highlights included: Case 1: A patient who had progressed on taxanes and ARPIs achieved resolution of disease on both PSMA-PET and whole-body MRI after 9 weeks, with PSA levels falling from 99 to 0.5 ng/mL. Case 2 (Visceral Disease): A heavily pre-treated patient with multiple liver metastases achieved a 46% RECIST response and a metabolic response continuing beyond 10 cycles. Case 3 (Post-Radioligand): A patient who had previously failed Actinium-PSMA therapy achieved a PSA drop from 100 to 0.03 ng/mL and regression of large nodal disease. Post-treatment biopsies confirmed increased T-cell infiltration in the tumor following four doses.
Conclusion and Outlook Prof. de Bono concluded that VAR5500 represents a significant step toward an immunotherapy that works safely and effectively in mCRPC. By successfully abrogating the risk of severe CRS through its innovative dual-masking platform, VAR5500 allows for deep and durable clinical responses, even in patients with high-burden visceral disease and those who have failed multiple lines of prior therapy. These findings provide a strong foundation for further clinical development and highlight the potential for a new standard of care in precision immunology for prostate cancer.
